Advertisement
Advertisement
CELC
Celcuity Inc. Common Stock
82.46
USDSponsored
+0.19
+0.23%
Jul 28, 15:59 UTC -4
Closed
After-Market
82.59
+0.13
+0.16%
CELC Earnings Reports
Positive Surprise Ratio
CELC beat 20 of 35 last estimates.
57%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.18
Implied change from Q1 26 (Revenue/ EPS)
--
/+21.65%
Implied change from Q2 25 (Revenue/ EPS)
--
/+13.46%
Celcuity Inc. Common Stock earnings per share and revenue
On May 14, 2026, CELC reported earnings of -0.97 USD per share (EPS) for Q1 26, beating the estimate of -1.07 USD, resulting in a 9.67% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.20% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -1.18 USD, with revenue projected to reach -- USD, implying an increase of 21.65% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Repligen Corp
Report Date
Jul 28, 2026 For Q2 26
Estimate
$0.45
Actual
$0.54
Surprise
+18.01%
Alkermes Inc. plc
Report Date
Jul 28, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.00
Surprise
+100.00%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Report Date
Jul 28, 2026 For Q2 26
Estimate
$0.30
Actual
$0.30
Surprise
-1.54%
AstraZeneca PLC
Report Date
Jul 27, 2026 For Q2 26
Estimate
$2.55
Actual
$2.63
Surprise
+3.12%
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.33
Surprise
+16.53%
Incyte Genomics Inc
Report Date
Jul 28, 2026 For Q2 26
Estimate
$2.14
Actual
$3.09
Surprise
+44.14%
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.17
Surprise
+49.72%
NeoGenomics, Inc.
Report Date
Jul 28, 2026 For Q2 26
Estimate
$0.03
Actual
$0.05
Surprise
+51.06%
Nautilus Biotechnolgy, Inc. Common Stock
Report Date
Jul 28, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.11
Surprise
+20.12%
Alzamend Neuro, Inc. Common Stock
Report Date
Jul 22, 2026 For Q4 26
Estimate
-$0.68
Actual
-$0.47
Surprise
+31.23%
FAQ
What were Celcuity Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Celcuity Inc. Common Stock reported EPS of -$0.97, beating estimates by 9.67%, and revenue of $0.00, 0% as expectations.
How did the market react to Celcuity Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 2.2%, changed from $134.72 before the earnings release to $137.68 the day after.
When is Celcuity Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Celcuity Inc. Common Stock's next earnings report?
Based on 9
analysts, Celcuity Inc. Common Stock is expected to report EPS of -$1.18 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement